Download PDF
Thromb Haemost 2017; 117(03): 644-646
DOI: 10.1160/TH16-09-0674
Letters to the Editor
Schattauer GmbH

Contrasting effects of myeloid and endothelial ADAM17 on atherosclerosis development

Emiel P.C. van der Vorst   #
1   Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, Germany
,
Zhen Zhao   #
1   Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, Germany
,
Martina Rami
1   Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, Germany
,
Lesca M. Holdt
2   Institute of Laboratory Medicine, Ludwig-Maximilians-University Munich, Munich, Germany
,
Daniel Teupser
2   Institute of Laboratory Medicine, Ludwig-Maximilians-University Munich, Munich, Germany
,
Sabine Steffens   *
1   Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, Germany
3   DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Germany
,
Christian Weber   *
1   Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, Germany
3   DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Germany
4   Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands
› Author Affiliations
Further Information

Publication History

Received: 01 September 2016

Accepted after major revision: 03 December 2016

Publication Date:
28 November 2017 (online)

Also available at
    Permissions and Reprints

Note: The review process for this manuscript was fully handled by Gregory Y. H. Lip, Editor in Chief.

Notes

# Shared first authorship


Notes

* Shared senior authorship


 

  • References

  • 1 Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med 2008; 29: 258-289.
    CrossrefPubMedGoogle Scholar
  • 2 Dreymueller D, Pruessmeyer J, Groth E. et al. The role of ADAM-mediated shedding in vascular biology. Eur J Cell Biol 2012; 91: 472-485.
    CrossrefPubMedGoogle Scholar
  • 3 Scheller J, Chalaris A, Garbers C. et al. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol 2011; 32: 380-387.
    CrossrefPubMedGoogle Scholar
  • 4 van der Vorst EP, Keijbeck AA, de Winther MP. et al. A disintegrin and metalloproteases: molecular scissors in angiogenesis, inflammation and atherosclerosis. Atherosclerosis 2012; 224: 302-308.
    CrossrefPubMedGoogle Scholar
  • 5 Garton KJ, Gough PJ, Philalay J. et al. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem 2003; 278: 37459-37464.
    CrossrefPubMedGoogle Scholar
  • 6 Hundhausen C, Schulte A, Schulz B. et al. Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes. J Immunol 2007; 178: 8064-8072.
    CrossrefPubMedGoogle Scholar
  • 7 Ludwig A, Weber C. Transmembrane chemokines: versatile ’special agents’ in vascular inflammation. Thromb Haemost 2007; 97: 694-703.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Tsakadze NL, Sithu SD, Sen U. et al. Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J Biol Chem 2006; 281: 3157-3164.
    CrossrefPubMedGoogle Scholar
  • 9 Canault M, Peiretti F, Kopp F. et al. The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: possible contribution to elevated plasma levels of soluble TNF alpha receptors. Atherosclerosis 2006; 187: 82-91.
    CrossrefPubMedGoogle Scholar
  • 10 Satoh M, Ishikawa Y, Itoh T. et al. The expression of TNF-alpha converting enzyme at the site of ruptured plaques in patients with acute myocardial infarction. Eur J Clin Invest 2008; 38: 97-105.
    CrossrefPubMedGoogle Scholar
  • 11 Holdt LM, Thiery J, Breslow JL. et al. Increased ADAM17 mRNA expression and activity is associated with atherosclerosis resistance in LDL-receptor deficient mice. Arterioscl Thromb Vasc Biol 2008; 28: 1097-1103.
    CrossrefPubMedGoogle Scholar
  • 12 Nicolaou A, Zhao Z, Northoff BH. et al. Adam17-deficiency promotes atherosclerosis by enhanced TNFR2 signaling in mice. Arterioscl Thromb Vasc Biol. 2016 in press.
    PubMedGoogle Scholar
  • 13 Horiuchi K, Kimura T, Miyamoto T. et al. Cutting edge: TNF-alpha-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. J Immunol 2007; 179: 2686-2689.
    CrossrefPubMedGoogle Scholar
  • 14 MacKenna DA, Omens JH, Covell JW. Left ventricular perimysial collagen fibers uncoil rather than stretch during diastolic filling. Basic Res Cardiol 1996; 91: 111-122.
    CrossrefPubMedGoogle Scholar
  • 15 van der Vorst EP, Jeurissen M, Wolfs IM. et al. Myeloid A disintegrin and metalloproteinase domain 10 deficiency modulates atherosclerotic plaque composition by shifting the balance from inflammation toward fibrosis. Am J Pathol 2015; 185: 1145-1155.
    CrossrefPubMedGoogle Scholar
  • 16 Weber S, Saftig P. Ectodomain shedding and ADAMs in development. Development 2012; 139: 3693-3709.
    CrossrefPubMedGoogle Scholar
  • 17 Arribas J, Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr Pharmaceut Design 2009; 15: 2319-2335.
    CrossrefPubMedGoogle Scholar
  • 18 Maretzky T, McIlwain DR, Issuree PD. et al. iRhom2 controls the substrate selectivity of stimulated ADAM17-dependent ectodomain shedding. Proc Natl Acad Sci USA 2013; 110: 11433-11438.
    CrossrefPubMedGoogle Scholar
  • 19 Adrain C, Zettl M, Christova Y. et al. Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science 2012; 335: 225-228.
    CrossrefPubMedGoogle Scholar